#141: TheMachine: TYSABRI(R) Demonstrates Sustained Improvement in Functional Outcomes in Multiple Sclerosis Patients According to New Post-Hoc Analysis
-- TYSABRI is the Only Marketed MS Treatment to Show
Both... |
September 20, 2008
01:07:55 AM |
#140: TheMachine: Biogen Idec and Elan Will Host a Conference Call For the Investment Community
Biogen Idec Inc.(NASDAQ: BIIB) and Elan (NYSE: ELN) today announced it... |
August 7, 2008
07:29:39 AM |
#139: FastFun: Biogen Idec Completes Review of Strategic Alternatives
Company to Remain Independent
The Board of Directors of Biogen Idec... |
December 13, 2007
01:01:33 PM |
#138: NewsBot: Biogen Idec Completes Review of Strategic Alternatives
Biogen Idec Completes Review of Strategic Alternatives
Company to Remain... |
December 13, 2007
10:13:40 AM |
#137: FastFun: Biogen Idec Issues Statement
Biogen Idec Inc. (NASDAQ: BIIB) today announced that its Board of... |
October 17, 2007
11:47:57 PM |
#136: FastFun: Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
- Phase 2 monotherapy trial to be initiated by end of 2007 -
PRAGUE,... |
October 17, 2007
11:47:06 PM |
#135: Jason: BIIB, Jacobs Receives Contract From Biogen Idec for Biotechnology Project in Denmark
Jacobs Engineering Group Inc. (NYSE: JEC) announced today that they received a... |
May 18, 2007
09:12:37 PM |
#134: NewsBot: BIIB News Biogen Idec To Report First Quarter 2007 Financial Results on May 2, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB) today announced... |
April 2, 2007
11:44:00 AM |
#133: NewsBot: BIIB News Biogen Idec to Present at the Cowen & Company 27th Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) announced today... |
March 6, 2007
02:03:00 PM |
#132: NewsBot: BIIB News Biogen Idec Reports Full Year and Fourth Quarter 2006 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB), a global... |
February 15, 2007
04:39:00 AM |
#131: NewsBot: BIIB News Biogen Idec Announces Webcast of Presentation at the Wachovia Securities 2007 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ:BIIB) announced today... |
January 23, 2007
08:45:00 AM |
#130: NewsBot: BIIB News Biogen Idec To Report Fourth Quarter 2006 Financial Results on February 15, 2007
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB) today announced... |
January 17, 2007
07:07:00 AM |
#129: NewsBot: BIIB News Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) announced today that... |
January 9, 2007
06:00:00 AM |
#128: NewsBot: BIIB News Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
DUBLIN, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:... |
December 15, 2006
06:10:00 AM |
#127: NewsBot: BIIB News Phase I/II Data Support Continued Development of Biogen Idec's Novel Anti-CD23 Antibody for Chronic Lymphocytic Leukemia
ORLANDO, Fla.--(BUSINESS WIRE)--Biogen Idec (Nasdaq: BIIB) announced data from a... |
December 10, 2006
03:00:00 PM |
| 
| 
| 
| 
| 
| 
